Bailard, Inc. Viking Therapeutics, Inc. Transaction History

Bailard, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 03, 2021	SELL	$5.3 - $6.71 $247,616 - $313,491	-46,720 Closed	0 $0
Q3 2020 Nov 10, 2020	SELL	$5.73 - $8.11 $1.49 Million - $2.11 Million	-260,480 Reduced 84.79%	46,720 $272,000
Q2 2020 Aug 12, 2020	SELL	$4.35 - $8.08 $434,999 - $808,000	-100,000 Reduced 24.56%	307,200 $2.22 Million
Q1 2020 Apr 16, 2020	BUY	$3.45 - $7.95 $475,065 - $1.09 Million	137,700 Added 51.09%	407,200 $1.91 Million
Q4 2019 Jan 31, 2020	SELL	$6.38 - $8.73 $345,158 - $472,293	-54,100 Reduced 16.72%	269,500 $2.16 Million
Q3 2019 Oct 18, 2019	BUY	$6.55 - $8.6 $39,300 - $51,600	6,000 Added 1.89%	323,600 $2.23 Million
Q2 2019 Jul 26, 2019	BUY	$7.67 - $10.63 $41,418 - $57,402	5,400 Added 1.73%	317,600 $2.64 Million
Q1 2019 Apr 24, 2019	BUY	$7.58 - $9.94 $1.24 Million - $1.62 Million	163,200 Added 109.53%	312,200 $3.1 Million
Q4 2018 Feb 05, 2019	BUY	$7.16 - $16.21 $1.07 Million - $2.42 Million	149,000 New	149,000 $1.14 Million

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.